A recent study highlights the need to continually monitor the cognitive development of children who were born very preterm.
Children born at a gestational age (GA) of 22 to 27 weeks are at significant risk of cognitive impairment at age 6.5 years, as are a substantial proportion of children born at a GA of 28-31 weeks. However, whereas neonatal conditions affect the prevalence of cognitive impairment of the former group (extremely preterm), these associations are not as evident in those in the latter group (very pre-term), according to a recent study.
Swedish investigators divided pre- term infants into 2 groups—those born extremely preterm (EPT) and those born very preterm (VPT). They assessed both groups for neurodevelopment at age 2.5 years and for cognitive outcomes at 6.5 years. Both assessments revealed mild-to-severe neurodevelopmental impairment. At 6.5 years, 8 of 91 children tested were diagnosed with cerebral palsy (4 VPT and4EPT)and6(4VPTand2EPT) with autism. Three of these 14 children had both cerebral palsy and autism. Neonatal factors independently related to 6.5-year outcomes were GA, retinopathy of prematurity, and treated persistent ductus arteriosus. But cognitive test scores at 2.5 years explained only 44% of intelligence score variance at 6.5 years. Given these results, the authors recommend following up into school age all children born before 32 weeks’ GA.
Thoughts from Dr. Farber
The test results at 2.5 years were corrected for prematurity. Although correction may be valid for younger children, I have always been leery that it is misleading by 2.5 years, presenting an overly optimistic picture. Unless the cognitive development of an extremely preterm child is solidly normal at 2.5 years, he or she still needs to be monitored closely.
This article was originally published on Contemporary Pediatrics®.
Reference
1. Kaul YF, Naseh N, Brodd KS, Böhm B, Holmström G, Hellström-Westas L. Average 2.5-year neurodevelop- mental test results in children born very preterm did not rule out cognitive deficits at 6.5 years of age. Acta Paediatr. 2021;110(3):846-854. doi:10.1111/apa.15586
FDA grants 510(k) clearance to cobas liat STI multiplex assay panels
Published: January 22nd 2025 | Updated: January 22nd 2025The new panels, leveraging rapid polymerase chain reaction technology, allow point of care sexually transmitted infection diagnosis in 20 minutes, enhancing targeted treatment and reducing follow-up losses.
Read More
Study highlights need for interventions to prevent postpartum smoking relapse
January 21st 2025Smoking cessation during pregnancy not only reduces pregnancy complications but also lowers the risk of relapse and new smoking initiation in the first postpartum year, according to a recent study.
Read More
Timely surveillance reported in under half of HPV-positive patients
January 20th 2025A recent study highlights gaps in cervical cancer screening compliance, with fewer than 50% of human papillomavirus-positive, negative for intraepithelial lesion or malignancy patients receiving recommended follow-up testing within the guideline time frame.
Read More